Metamark is leading a shift in urological cancer care to enable patients and their physicians to make informed tretment decisions that lead to better quality of life and lower cost of care.

LEARN MORE

Press Release

ProMark® Prostate Cancer Prognostic now included in NCCN Guidelines

Metamark, a leader in commercializing high-value urologic oncology products, today announced that ProMark®, the first and only protein-based prognostic test for early-stage prostate cancer, has been included in the 2016 National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines.

read article
Press Release

Study Demonstrates Cost-effectiveness of New Assay to Inform Treatment Decisions Compared to Guidelines-based Care

Data published in The Oncologist support use of ProMark® as a likely cost-effective addition to current guidelines for management of Gleason 3+3 and 3+4 early-stage prostate cancer.

read article
Displaying results 3-4 (of 12)
 |<  <  1 - 2 - 3 - 4 - 5 - 6  >  >|